Standard BioTools to Participate in Upcoming Investor Conferences
22 Maggio 2024 - 10:01PM
Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today
announced that its management team will participate in the
following investor conferences in the month of June:
- Jefferies Global Healthcare
Conference on June 5th & 6th 2024. President and CEO, Michael
Egholm, PhD, will participate in a fireside chat on Wednesday June
5th at 2:30 p.m. ET
- Scotiabank Healthcare 1x1 Day on
June 20th 2024. Management will participate in 1x1 investor
meetings in Toronto, Canada
- TD Cowen’s 3rd Annual Tool/Dx
Revolution Conference, June 24th - 26th 2024. President and CEO,
Michael Egholm, PhD, will participate in a Panel Discussion: Deal
or No Deal – M&A Consolidation and Combination as a Path to
Growth on Tuesday, June 25th at 11:50 a.m. PT
Available presentations will be webcast live and available on
the Investor Relations page of the Company’s website at Events
& Presentations. A recording will be archived and available on
the Standard BioTools Investor Relations page at
investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of
SomaLogic Inc. and previously known as Fluidigm Corporation, has an
established portfolio of essential, standardized next-generation
technologies that help biomedical researchers develop medicines
faster and better. As a leading solutions provider, the company
provides reliable and repeatable insights in health and disease
using its proprietary mass cytometry and microfluidics
technologies, which help transform scientific discoveries into
better patient outcomes. Standard BioTools works with leading
academic, government, pharmaceutical, biotechnology, plant and
animal research and clinical laboratories worldwide, focusing on
the most pressing needs in translational and clinical research,
including oncology, immunology and immunotherapy. Learn more at
standardbio.com or connect with us on X, Facebook®, LinkedIn, and
YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply:
www.standardbio.com/legal/salesterms. Patent and License
Information: www.standardbio.com/legal/notices. Trademarks:
www.standardbio.com/legal/trademarks. Any other trademarks are the
sole property of their respective owners. ©2024 Standard BioTools
Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
David HolmesGilmartin Group LLC(332)
330-1031ir@standardbio.com
Grafico Azioni Standard BioTools (NASDAQ:LAB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Standard BioTools (NASDAQ:LAB)
Storico
Da Dic 2023 a Dic 2024